EPISODE · Sep 22, 2021 · 7 MIN
The Keynote 716 trial - report from ESMO2021
from Medical Digest & Congress Report · host Medical Congress News
Prof. Jason J. Luke speaks about the efficacy and safety results from the Keynote 716 double-blinded phase III trial. Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma. Video: https://congressreport.eu/scientific-contents/interview:keynote-716-trial
Embed this episode
NOW PLAYING
The Keynote 716 trial - report from ESMO2021
0:00
7:04
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Medical Digest & Congress Report?
This episode is 7 minutes long.
When was this Medical Digest & Congress Report episode published?
This episode was published on September 22, 2021.
Can I download this Medical Digest & Congress Report episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!